Assessment for Hormone Replacement Therapy
Women considering hormone replacement therapy should be assessed using a systematic algorithm that evaluates age/timing since menopause, symptom severity, cardiovascular risk, breast cancer risk, and absolute contraindications—with therapy recommended for symptomatic women under age 60 or within 10 years of menopause who lack contraindications. 1, 2
Patient Selection Algorithm
Step 1: Verify Timing Window
The "window of opportunity" is critical for favorable benefit-risk ratio:
- Age < 60 years OR < 10 years since menopause onset = Proceed with assessment 1, 2
- Age ≥ 60 years OR ≥ 10 years since menopause = Consider alternative options due to increased absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia 2
Step 2: Identify Absolute Contraindications
Avoid HRT if any of the following are present: 1
- Unexplained vaginal bleeding
- History of stroke, transient ischemic attack, myocardial infarction, pulmonary embolism, or venous thromboembolism
- Current or history of breast cancer or endometrial cancer
- Active liver disease
Step 3: Evaluate High-Risk Conditions Requiring Caution
Exercise caution and consider alternatives if: 1
- Diabetes mellitus
- Hypertriglyceridemia
- Active gallbladder disease
- Elevated breast cancer risk (family history, genetic mutations, dense breast tissue)
- Elevated cardiovascular disease risk
- Migraine with aura
Step 4: Assess Symptom Severity
Primary indications for systemic HRT:
- Moderate to severe vasomotor symptoms (hot flashes, night sweats)
- Sleep disturbance related to menopause
- Menopause-associated anxiety or depressive symptoms
- Arthralgias
- Prevention of bone loss/osteoporosis 1
For isolated genitourinary symptoms (vaginal dryness, dyspareunia, dysuria, urinary frequency) without vasomotor symptoms, use low-dose vaginal estrogen, vaginal dehydroepiandrosterone, or oral ospemifene rather than systemic therapy 2.
Recommended Hormone Regimens
For Women WITH an Intact Uterus
Estrogen plus progestogen therapy (EPT) is mandatory to prevent endometrial hyperplasia and cancer 1:
- Transdermal estrogen is preferred over oral formulations due to lower thrombotic risk 3
- Use progestogens structurally close to progesterone for improved breast tissue safety 4
- Lowest effective estrogen dose should be used
For Women WITHOUT a Uterus (Post-Hysterectomy)
Estrogen therapy (ET) alone 1:
- Transdermal estrogen preferred
- No progestogen needed
- Conjugated equine estrogens showed more favorable results in younger women (50-59 years) for all-cause mortality and myocardial infarction in the WHI trial 5
Alternative Option
Tibolone (where available) for women without a uterus 1
Duration and Monitoring
Treatment duration: Should be based on persistent documented indications (ongoing vasomotor symptoms), with shared decision-making and periodic reevaluation 2. For women with treatment-induced premature ovarian insufficiency, continue HRT until the average age of natural menopause 6.
Timing of initiation:
- May be initiated immediately after surgical menopause
- Following chemotherapy, assess ovarian recovery before confirming permanent ovarian insufficiency 6
Critical Pitfalls to Avoid
Do not initiate HRT in women beyond the 10-year window without compelling indications—the absolute risks outweigh benefits 2
Never prescribe estrogen alone to women with an intact uterus—this dramatically increases endometrial cancer risk 1
Defer HRT during active chemotherapy or bevacizumab treatment due to cumulative thrombotic risk 6
Do not use oral estrogen in women with elevated thrombotic risk—transdermal formulations have superior safety profiles 3
Avoid treating genitourinary symptoms alone with systemic HRT—vaginal estrogen is safer and equally effective 2
The evidence strongly supports that bioidentical and transdermal hormones demonstrate safer cardiovascular profiles compared to oral synthetic preparations 3, making them the preferred formulation when initiating therapy within the appropriate timing window.